ArticleScientific reports2025
Real-world efficacy and safety of pembrolizumab plus lenvatinib in patients with metastatic renal cell carcinoma: a multi-institutional retrospective study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Efficacy, safety, and treatment feasibility of pembrolizumab plus lenvatinib in patients aged 75 years or older with advanced renal cell carcinoma: a Japanese multicenter retrospective study.International journal of clinical oncology · 2026Article
- Comparison of effectiveness and safety of pembrolizumab plus lenvatinib versus nivolumab plus cabozantinib for metastatic renal cell carcinoma: a real-world study.International journal of clinical oncology · 2026Article
- Real-World Effectiveness and Safety of Pembrolizumab-Lenvatinib Versus Axitinib-Based Regimens in Metastatic Clear Cell Renal Cell Carcinoma: A Multicenter Retrospective Study.International journal of urology : official journal of the Japanese Urological Association · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the potential of pembrolizumab and lenvatinib combination therapy in treating metastatic renal cell carcinoma (mRCC), real-world evidence on its efficacy and safety remains limited. We retrospectively analyzed data from 118 patients with mRCC who initiated pembrolizumab plus lenvatinib as first-line therapy between August 2022 and March 2024. Patient characteristics, treatment outcomes, and adverse events were evaluated. Oncological outcomes were stratified following the International Metastatic RCC Database Consortium risk classification. The objective response and disease control rates were 69.5% and 98.5%, respectively. Median progression-free survival (PFS) was 26.8 months (95% confidence interval (CI), 23.5-27.8)), whereas the median overall survival (OS) was not reached (95%CI, 20.5- not reached). Grade ≥ 3 treatment-related adverse events occurred in 39.8% of all patients. Clinical outcomes were also compared between patients aged ≥ 75 and < 75 years. Median age was 70 years; 70.3% and 29.7% aged < 75 and ≥ 75 years, respectively. No significant differences were observed in PFS and OS between the two groups (p = 0.14 and p = 0.44, respectively). Pembrolizumab plus lenvatinib demonstrated favorable efficacy and manageable safety in a real-world cohort of patients with mRCC, including older adults.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.